Intriguingly, studies suggest that SMARCB1, a recognized tumor suppressor gene in various cancers, may play a significant role influencing sensitivity to EGFR-TKI-based therapy in malignant rhabdoid tumors (MRT). This evidence concerns the gene EGFR and cancer.